Colin Edwards. Cardiologist Auckland Heart Group Waitemata Health

Similar documents
Colin Edwards. Cardiologist Auckland Heart Group Waitemata Health

Management of Hypertension and Consequences of non-compliance. Colin Edwards

HYPERTENSION CHAT with Colin and Ted AUG 2015

The State of Hypertension in NZ in 2010 personal view

Preventing and Treating High Blood Pressure

Update in Hypertension

Managing Hypertension in 2016

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Modern Management of Hypertension: Where Do We Draw the Line?

HYPERTENSION. Introduction. Colin Edwards Cardiologist AHG and WDHB

ADVANCES IN MANAGEMENT OF HYPERTENSION

Modern Management of Hypertension

Hypertension Pharmacotherapy: A Practical Approach

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

ADVANCES IN MANAGEMENT OF HYPERTENSION

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Management of Hypertension

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Hypertension Management in Diabetic Patients

CKD & HT. Anne-Marie Angus

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Hypertension Update Clinical Controversies Regarding Age and Race

Treating Hypertension from

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Managing HTN in the Elderly: How Low to Go

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Patrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Antihypertensive drugs: I. Thiazide and other diuretics:

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Difficult to Treat Hypertension

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Management Controversies in the Elderly Patient

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

Pharmacologic Management of Hypertension

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Cardiac Pathophysiology

Hypertension Update 2009

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Incidental Findings; Management of patients presenting with high BP. Phil Swales

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Antihypertensive Trial Design ALLHAT

Objectives. Describe results and implications of recent landmark hypertension trials

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016

STANDARD treatment algorithm mmHg

Treating Hypertension in 2018: What Makes the Most Sense Today?

The Failing Heart in Primary Care

What s In the New Hypertension Guidelines?

Approach to patient with hypertension. Dr. Amitesh Aggarwal

Hypertension and Cardiovascular Disease

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Hypertension Management: A Moving Target

Hypertension in the very old. Objectives: Clinical Perspective

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB

How do we diagnose hypertension today? Presentation Subtitle

The Latest Generation of Clinical

Creative blood pressure management: whys and the tricks

Byvalson. (nebivolol, valsartan) New Product Slideshow

How Low Do We Go? Update on Hypertension

Treating Hypertension in Individuals with Diabetes

Jared Moore, MD, FACP

5.2 Key priorities for implementation

Management of Hypertension in Women

CVD Risk of Hypertension. Regina Giblin CVD Clinical Development Coordinator

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Management of High Blood Pressure in Adults

By Prof. Khaled El-Rabat

LXIV: DRUGS: 4. RAS BLOCKADE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D

Randomized Design of ALLHAT BP Trial

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

The real picture. Prorenin (Renin) PRR AT3 AT4. AT4 receptor. PAI 1 Abassi, Biochem Pharm, 2009

Adult Blood Pressure Clinician Guide June 2018

Overview. NOT A REPETION OF LOCAL GUIDELINE Dr Diviash Thakrar

Talking about blood pressure

Clinical Recommendations: Patients with Periodontitis

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention

Transcription:

Colin Edwards Cardiologist Auckland Heart Group Waitemata Health August 2011

BP MEASUREMENTS measured seated mean of 2 or BP recordings at least 2 visits 2 x risk of developing true hypertension

Size of problem: 20% of adults in Western societies have hypertension Accounts for 1 in 6 deaths 95% is essential hypertension

Trials 35-40% mean reduction in stroke 20-25% reduction in MI 50% reduction in heart failure Pt with BP 159/95 mmhg (stage 1) on treatment for 10 yrs 12mmHg prevent 1 death for every 11 pts reated

GP Referral 63 year old female patient, retired secretary, married Known coronary artery disease and peripheral vascular disease CV Risks: longstanding mild hypertension treated dyslipidemia ex-smoker ACUTE PROBLEM: acceleration of hypertension x 6months poor control despite 3 agents more breathless- struggling to finish 18 holes of golf

Stable Coronary Artery Disease at present: Unstable angina- PCI (2000) NSTEMI-RCA PCI (2002) NSTEMI severe proximal RCA-DES (2006) Peripheral Vascular Disease: PCI L iliac artery 2002

Cilazapril 5mg/d Metoprolol 23.75mg/d Amlodipine 5mg/d Lipitor 80mg/d- TC- 4.8mmol/l, HDL- 0.9 mmol/l, LDL- 2.8 mmol/l, TG-2.4 mmol/l Compliance prefer not to be on medication; occasionally forgets Resveritrol, 3 oil, and glucosamine- takes religiously

First diagnosed at age 40 years Mother was a bad hypertensive- RIP stroke at 65 yrs Normal BP control through 3 pregnancies in her late 20 s Enjoys salty snacks after golf- 19 th hole Alcohol- wine every night with evening meal- 1-2 glasses 1 or 2 drinks after golf No liquorice liquor Exercise- 2 rounds of golf per week Uses Voltaren 75mg before golf bad back No HRT No hx of malignant phase ht, renal failure or heart failure STRESS?? work, financial, leaky home, son divorce etc...

Appeared a little anxious BMI-30 BP-190/110mmHg; PR-90 bpm Fundi- arteriolar narrowing Heart sounds- S4, S1, S2 no CHF Abdomen- peri-umbilical bruit bruits over both femoral arteries ECG- SR (p-mitrale), inferior Q waves, LV voltages + lateral strain pattern Creatinine-63umol/l, K+ 4.8mmol/l Fasting glucose-5.8mmol/l Urine-+proteinuria Thyroid functions-normal

45/48 interpretable measurements >95% 24 hour mean-168/93 mmhg (normal <135/85mmHg) non-dipper - minimal drop (6%) in nocturnal BP measurements

Significant hypertension- possibly resistant 3 anti-hypertensive agents- no diuretic, low doses of meds?compliance; NSAID; salty snacks; BMI End organ involvement-lvh, CAD, PVD, proteinuria Acceleration of hypertension x 6months? Secondary-RAS Loss of nocturnal dipping Para-umbilical bruit Vasculopath- stable coronary disease peripheral vascular disease

VOLUME EXPANSION: Vasodilators (ACE and Amlodipine)-lead to fluid retention OR volume expansion due to efferent arteriolar dilatation. Add low dose diuretic e.g. Inhibace plus

Study began 1994 x 8yrs 40 000 pts Aim:? Best drug to start Rx. Results: SBP -greatest with chlorthalidone Less CHF with chlorthalidone JNC VII- start with diuretic Hypertension 2006

Aim: Optimal combination Rx for ht Compared the effects of two combinations AML/ACE or HCTZ/ACE on major fatal and nonfatal cardiovascular events. 11 400 men and women 55 years or older who had SBP >160 mm Hg RESULTS: 20% in morbidity and mortality in AML/ACE group.?jnc-7 revision

HYVET- benefits and risks of reducing BP (SBP>160mmHg) in very elderly hypertensives. (aged 80 or more). BP lowering benefits could be offset by harm due to hypotension-related syncope. 3845 patients, international trial 11 different countries Followed for 2 years Elderly pts are prone to postural hypotension Monitor/measure BP s in the standing position RESULT: Treatment of hypertension Stroke 30% Mortality 21% Heart failure 64%

Inhibace Plus 1 daily Amlodipine 10 mg/d Metoprolol 47.5 mg/d Office BP 170/95mmHg Home Monitoring: Most levels elevated 150-160mmHg Home Monitoring: Encourage purchasing of unit Keep a diary to bring to clinic- NEED AT LEAST 12 MEASUREMENTS 2-3 readings per week, at rest, sitting. Normal <135/85mmHg Helps me adjust and uptitrate therapy Engages the patient- encourages and motivates pts to remain compliant

Right kidney-10cm; good cortical thickness Left kidney 11cm; good cortical thickness 85% STENOSIS- ORIGIN OF RIGHT RENAL ARTERY Resistive Index- 0.7 60% STENOSIS- ORIGIN OF LRA. Serum Cr: 63umol/l Urine: + proteinuria Refractory hypertension- 4 agents Probably has renal ischaemia, but still has good residual renal function.

Renal perfusion activation of juxta-glomerular cells Release of renin

Improve renal perfusion

2 trials ASTRAL (806 PTS), STAR(140 pts) -Endpoints-renal function, CV events, mortality -No benefit of stenting plus medical therapy over medical therapy alone -Limited by imprecise definitions of RAS, inclusion of pts with insignificant lesions, crossovers, multiple disease etc. CORAL- well designed multi-centre study. completion expected 2011 meantime revascularisation should be reserved for pts in whom aggressive medical therapy fails, trial participants.

Urine: + proteinuria Serum Cr- 64umol/l

On 4 medications plus renal artery stenting- 24 hr average of 154/88mmHg Need Better Treatments Direct Renin Inhibitor e.g. Aliskiren ACE Inhibitors Angiotensin Receptor blockers e.g. Losartan, candesartan

Circulation.2009;119:530-537

Take a good history- compliance, diet (salt), stress, alcohol, NSAID s Resistant hypertension- persistent ht despite good doses of 3 agents including a diuretic- ACE/ARB, Ca blocker, thiazide diuretic refer Need a good diuretic e.g. Chlorthalidone 25mg/d egfr <40mls/min Frusemide bd Maximise doses of ACE/ARB, calcium blockers If overweight- spironolactone 25mg/d Look at heart rate- good indicator of sympathetic activity B-Blocker Diltiazem with the amlodipine

Benefit in treating hypertension in the very elderly (HYVET) BP Target are lower- SBP-150mmHg Postural hypotension- monitor Rx in the standing position Promote home BP monitoring-engages the pt and improves compliance 24 hour BP monitoring in useful Useful information on nocturnal BP-dippers, non-dippers and risers

ahg@heartgroup.co.nz